[go: up one dir, main page]

EP2981525A4 - Dérivés de quinoléine multifonctionnels en tant qu'agents anti-neurodégénératifs - Google Patents

Dérivés de quinoléine multifonctionnels en tant qu'agents anti-neurodégénératifs

Info

Publication number
EP2981525A4
EP2981525A4 EP13881032.0A EP13881032A EP2981525A4 EP 2981525 A4 EP2981525 A4 EP 2981525A4 EP 13881032 A EP13881032 A EP 13881032A EP 2981525 A4 EP2981525 A4 EP 2981525A4
Authority
EP
European Patent Office
Prior art keywords
multifunctional
quinoline derivatives
neurodegenerative agents
neurodegenerative
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13881032.0A
Other languages
German (de)
English (en)
Other versions
EP2981525A1 (fr
Inventor
Ji-Wang Chern
Chen-Wei Huang
Pei-Teh Chang
Rahul Subhash Talekar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annji Pharmaceutical Co Ltd
Original Assignee
Annji Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharmaceutical Co Ltd filed Critical Annji Pharmaceutical Co Ltd
Publication of EP2981525A1 publication Critical patent/EP2981525A1/fr
Publication of EP2981525A4 publication Critical patent/EP2981525A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP13881032.0A 2013-04-02 2013-04-02 Dérivés de quinoléine multifonctionnels en tant qu'agents anti-neurodégénératifs Withdrawn EP2981525A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/034960 WO2014163622A1 (fr) 2013-04-02 2013-04-02 Dérivés de quinoléine multifonctionnels en tant qu'agents anti-neurodégénératifs

Publications (2)

Publication Number Publication Date
EP2981525A1 EP2981525A1 (fr) 2016-02-10
EP2981525A4 true EP2981525A4 (fr) 2016-12-21

Family

ID=51658752

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13881032.0A Withdrawn EP2981525A4 (fr) 2013-04-02 2013-04-02 Dérivés de quinoléine multifonctionnels en tant qu'agents anti-neurodégénératifs

Country Status (9)

Country Link
EP (1) EP2981525A4 (fr)
JP (1) JP6153179B2 (fr)
KR (1) KR101802048B1 (fr)
CN (1) CN105452224B (fr)
AU (1) AU2013385618B2 (fr)
BR (1) BR112015024472A2 (fr)
IL (1) IL241295A0 (fr)
RU (1) RU2642466C2 (fr)
WO (1) WO2014163622A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101725326B1 (ko) * 2015-04-23 2017-04-12 대한민국 항균활성을 갖는 신규 미생물 및 그를 이용한 슈덴 생산방법
CN105949120B (zh) * 2016-05-27 2018-07-24 广东工业大学 一种四齿螯合型单喹啉衍生物及其制备方法和作为神经退行性疾病的金属离子调节剂的应用
CN111646936A (zh) * 2020-06-22 2020-09-11 江苏亚虹医药科技有限公司 芳香醚类化合物的制备方法
KR102281647B1 (ko) * 2020-12-09 2021-07-30 메디케어제약 주식회사 피페라진-퀴놀린 유도체의 제조방법
CN113527200B (zh) * 2021-05-27 2022-12-02 北京斯利安药业有限公司 一种氯喹那多的制备方法
US20240246916A1 (en) * 2021-05-31 2024-07-25 Jiangsu Yahong Meditech Co., Ltd. 7-nitro-8-hydroxyquinoline derivatives, preparation method therefore and medical use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682927A (en) * 1968-06-15 1972-08-08 Massimo Carissimi 5,7-bichloro-8-hydroxy-2-acetylamino quinoline
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
ES2094567T3 (es) * 1992-10-27 1997-01-16 Janssen Pharmaceutica Nv Derivados de la 4-quinolinilo con actividad anti-helicobacter.
CN1114407C (zh) * 1996-08-13 2003-07-16 P·N·吉罗莱马托斯股份有限公司 螯合剂碘氯羟喹在制备用于治疗早老性痴呆的药物组合物中的用途
EP0957100B1 (fr) * 1997-07-07 2004-10-27 Kowa Co., Ltd. Derives de diamine et compositions pharmaceutiques les contenant
FR2819507B1 (fr) * 2001-01-17 2007-09-28 Inst Rech Developpement Ird Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
US7452888B2 (en) 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
JP2005536462A (ja) 2002-04-30 2005-12-02 ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド カスパーゼ−３阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2004215624B2 (en) * 2003-02-25 2011-06-02 Topotarget Uk Limited Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
WO2005035534A1 (fr) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Composes a anneau bicyclique heterocyclique et a anneau tricyclique heterocyclique et medicaments les contenant
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
FR2889525A1 (fr) * 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
CA2658793A1 (fr) * 2006-07-25 2008-02-07 Daniel Dumas Derives de quinoline
EP2350012B1 (fr) * 2008-10-06 2017-06-28 The Johns Hopkins University Composés de quinoline en tant qu'inhibiteurs de l'angiogenèse, de la méthionine aminopeptidase humaine et de la sirt1, et méthodes de traitement de troubles
NZ603789A (en) * 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
CN102526052B (zh) * 2012-01-19 2013-10-09 华南师范大学 一种2-糖基喹啉化合物在制备抗乙酰胆碱酯酶药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JI M ET AL: "Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 15, no. 6, 15 March 2005 (2005-03-15), pages 1701 - 1705, XP027800934, ISSN: 0960-894X, [retrieved on 20050315] *

Also Published As

Publication number Publication date
AU2013385618A1 (en) 2015-09-24
RU2642466C2 (ru) 2018-01-25
KR20150136070A (ko) 2015-12-04
RU2015137621A (ru) 2017-05-11
JP2016515617A (ja) 2016-05-30
JP6153179B2 (ja) 2017-06-28
CN105452224A (zh) 2016-03-30
CN105452224B (zh) 2017-12-26
EP2981525A1 (fr) 2016-02-10
KR101802048B1 (ko) 2017-12-28
IL241295A0 (en) 2015-11-30
WO2014163622A1 (fr) 2014-10-09
BR112015024472A2 (pt) 2017-07-18
AU2013385618B2 (en) 2017-01-05
WO2014163622A8 (fr) 2014-11-13

Similar Documents

Publication Publication Date Title
IL267031B (en) Selectively converted quinoline compounds
IL262970B (en) Quinoline compounds are selectively converted
ZA201506880B (en) Quinolines derivatives as novel anticancer agents
ZA201600514B (en) Quinoline derivative
IL240863A0 (en) Amatoxin derivatives
SG11201505309TA (en) Benzylamine derivatives
SG11201506100XA (en) Pyridazinone-amides derivatives
IL243249A0 (en) History of diazacarbazole as ligands of tau –pet
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
IL241295A0 (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents
SG11201605189YA (en) Imidazopyrazinone derivatives
ZA201504873B (en) Benzylamine derivatives
GB201300649D0 (en) Cyclization
GB201314960D0 (en) Heterocyclic derivatives
GB201300306D0 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150904

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/47 20060101ALI20160805BHEP

Ipc: A61P 25/28 20060101ALI20160805BHEP

Ipc: C07D 215/26 20060101AFI20160805BHEP

Ipc: C07D 215/28 20060101ALI20160805BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20161111BHEP

Ipc: C07D 215/28 20060101ALI20161111BHEP

Ipc: C07D 215/26 20060101AFI20161111BHEP

Ipc: A61K 31/47 20060101ALI20161111BHEP

17Q First examination report despatched

Effective date: 20170421

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180503